Cargando…

Long-term survival of screen-detected synchronous and metachronous bilateral non-palpable breast cancer among Chinese women: a hospital-based study (2003–2017)

PURPOSE: Screen-detected unilateral non-palpable breast cancer (NPBC) shows favorable prognosis, whereas bilateral breast cancer (BBC), especially synchronous BBC (SBBC) manifests worse survival than unilateral breast cancer (BC). It remains unclear whether screen-detected bilateral NPBC has comprom...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Bo, Xu, Ying, Zhou, Yidong, Yao, Ru, Zhou, Xingtong, Xu, Yali, Ren, Xinyu, Xiao, Mengsu, Zhu, Qingli, Kong, Lingyan, Mao, Feng, Lin, Yan, Zhang, Xiaohui, Shen, Songjie, Sun, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581860/
https://www.ncbi.nlm.nih.gov/pubmed/36166112
http://dx.doi.org/10.1007/s10549-022-06747-5
_version_ 1784812722867666944
author Pan, Bo
Xu, Ying
Zhou, Yidong
Yao, Ru
Zhou, Xingtong
Xu, Yali
Ren, Xinyu
Xiao, Mengsu
Zhu, Qingli
Kong, Lingyan
Mao, Feng
Lin, Yan
Zhang, Xiaohui
Shen, Songjie
Sun, Qiang
author_facet Pan, Bo
Xu, Ying
Zhou, Yidong
Yao, Ru
Zhou, Xingtong
Xu, Yali
Ren, Xinyu
Xiao, Mengsu
Zhu, Qingli
Kong, Lingyan
Mao, Feng
Lin, Yan
Zhang, Xiaohui
Shen, Songjie
Sun, Qiang
author_sort Pan, Bo
collection PubMed
description PURPOSE: Screen-detected unilateral non-palpable breast cancer (NPBC) shows favorable prognosis, whereas bilateral breast cancer (BBC), especially synchronous BBC (SBBC) manifests worse survival than unilateral breast cancer (BC). It remains unclear whether screen-detected bilateral NPBC has compromised survival and requires intensified treatment or favorable prognosis and needs de-escalating therapy. METHODS: From 2003 to 2017, 1,075 consecutive NPBC patients were retrospectively reviewed. There were 988 patients with unilateral NPBC (UniNPBC), and 87 patients with ipsilateral NPBC + any contralateral BC [(N + AnyContra) PBC], including 32 patients with bilateral NPBC (BiNPBC) and 55 patients with ipsilateral NPBC + contralateral palpable cancer [(N + Contra) PBC]. Median follow-up time was 91 (48–227) months. Clinicopathological characteristics were compared between UniNPBC and BBC, whereas relapse-free survival (RFS) and overall survival (OS) among BBC subgroups. RFS and OS factors of BBC were identified. RESULTS: Compared to UniNPBC, patients with screen-detected bilateral BC had more invasive (85.1%, 74.8%), ER negative (26.4%, 17.1%), PR negative (36.8%, 23.5%), triple-negative (21.6%, 8.5%) BC as well as less breast conserving surgery (17.2%, 32.4%), radiotherapy (13.8%, 32.0%) and endocrine therapy (71.3%, 83.9%). 10 year RFS and OS rates of (N + AnyContra) PBC (72.8%, 81.5%), (N + Contra) PBC (60.6%, 73.9%), and synchronous (N + Contra) PBC (58.1%, 70.1%) were significantly compromised compared to UniNPBC (91.0%, 97.2%). RFS factors of BBC included pN3 (p = 0.048), lymphovascular invasion (p = 0.008) and existence of contralateral palpable interval BC (p = 0.008), while the OS relevant factor was pN3 (p = 0.018). CONCLUSION: Screen-detected bilateral NPBC including SynBiNPBC and MetaBiNPBC showed good prognosis as UniNPBC so that the therapy of BiNPBC could be de-escalated and optimized according to UniNPBC. Contrarily, screen-detected ipsilateral NPBC with contralateral palpable BC [(N + Contra) PBC] manifested unfavorable survival worse than UniNPBC and synchronous (N + Contra) PBC had the worst survival among all subgroups, implying that these were actually bilateral interval BC and required intensified treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-022-06747-5.
format Online
Article
Text
id pubmed-9581860
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-95818602022-10-21 Long-term survival of screen-detected synchronous and metachronous bilateral non-palpable breast cancer among Chinese women: a hospital-based study (2003–2017) Pan, Bo Xu, Ying Zhou, Yidong Yao, Ru Zhou, Xingtong Xu, Yali Ren, Xinyu Xiao, Mengsu Zhu, Qingli Kong, Lingyan Mao, Feng Lin, Yan Zhang, Xiaohui Shen, Songjie Sun, Qiang Breast Cancer Res Treat Epidemiology PURPOSE: Screen-detected unilateral non-palpable breast cancer (NPBC) shows favorable prognosis, whereas bilateral breast cancer (BBC), especially synchronous BBC (SBBC) manifests worse survival than unilateral breast cancer (BC). It remains unclear whether screen-detected bilateral NPBC has compromised survival and requires intensified treatment or favorable prognosis and needs de-escalating therapy. METHODS: From 2003 to 2017, 1,075 consecutive NPBC patients were retrospectively reviewed. There were 988 patients with unilateral NPBC (UniNPBC), and 87 patients with ipsilateral NPBC + any contralateral BC [(N + AnyContra) PBC], including 32 patients with bilateral NPBC (BiNPBC) and 55 patients with ipsilateral NPBC + contralateral palpable cancer [(N + Contra) PBC]. Median follow-up time was 91 (48–227) months. Clinicopathological characteristics were compared between UniNPBC and BBC, whereas relapse-free survival (RFS) and overall survival (OS) among BBC subgroups. RFS and OS factors of BBC were identified. RESULTS: Compared to UniNPBC, patients with screen-detected bilateral BC had more invasive (85.1%, 74.8%), ER negative (26.4%, 17.1%), PR negative (36.8%, 23.5%), triple-negative (21.6%, 8.5%) BC as well as less breast conserving surgery (17.2%, 32.4%), radiotherapy (13.8%, 32.0%) and endocrine therapy (71.3%, 83.9%). 10 year RFS and OS rates of (N + AnyContra) PBC (72.8%, 81.5%), (N + Contra) PBC (60.6%, 73.9%), and synchronous (N + Contra) PBC (58.1%, 70.1%) were significantly compromised compared to UniNPBC (91.0%, 97.2%). RFS factors of BBC included pN3 (p = 0.048), lymphovascular invasion (p = 0.008) and existence of contralateral palpable interval BC (p = 0.008), while the OS relevant factor was pN3 (p = 0.018). CONCLUSION: Screen-detected bilateral NPBC including SynBiNPBC and MetaBiNPBC showed good prognosis as UniNPBC so that the therapy of BiNPBC could be de-escalated and optimized according to UniNPBC. Contrarily, screen-detected ipsilateral NPBC with contralateral palpable BC [(N + Contra) PBC] manifested unfavorable survival worse than UniNPBC and synchronous (N + Contra) PBC had the worst survival among all subgroups, implying that these were actually bilateral interval BC and required intensified treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-022-06747-5. Springer US 2022-09-27 2022 /pmc/articles/PMC9581860/ /pubmed/36166112 http://dx.doi.org/10.1007/s10549-022-06747-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Epidemiology
Pan, Bo
Xu, Ying
Zhou, Yidong
Yao, Ru
Zhou, Xingtong
Xu, Yali
Ren, Xinyu
Xiao, Mengsu
Zhu, Qingli
Kong, Lingyan
Mao, Feng
Lin, Yan
Zhang, Xiaohui
Shen, Songjie
Sun, Qiang
Long-term survival of screen-detected synchronous and metachronous bilateral non-palpable breast cancer among Chinese women: a hospital-based study (2003–2017)
title Long-term survival of screen-detected synchronous and metachronous bilateral non-palpable breast cancer among Chinese women: a hospital-based study (2003–2017)
title_full Long-term survival of screen-detected synchronous and metachronous bilateral non-palpable breast cancer among Chinese women: a hospital-based study (2003–2017)
title_fullStr Long-term survival of screen-detected synchronous and metachronous bilateral non-palpable breast cancer among Chinese women: a hospital-based study (2003–2017)
title_full_unstemmed Long-term survival of screen-detected synchronous and metachronous bilateral non-palpable breast cancer among Chinese women: a hospital-based study (2003–2017)
title_short Long-term survival of screen-detected synchronous and metachronous bilateral non-palpable breast cancer among Chinese women: a hospital-based study (2003–2017)
title_sort long-term survival of screen-detected synchronous and metachronous bilateral non-palpable breast cancer among chinese women: a hospital-based study (2003–2017)
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581860/
https://www.ncbi.nlm.nih.gov/pubmed/36166112
http://dx.doi.org/10.1007/s10549-022-06747-5
work_keys_str_mv AT panbo longtermsurvivalofscreendetectedsynchronousandmetachronousbilateralnonpalpablebreastcanceramongchinesewomenahospitalbasedstudy20032017
AT xuying longtermsurvivalofscreendetectedsynchronousandmetachronousbilateralnonpalpablebreastcanceramongchinesewomenahospitalbasedstudy20032017
AT zhouyidong longtermsurvivalofscreendetectedsynchronousandmetachronousbilateralnonpalpablebreastcanceramongchinesewomenahospitalbasedstudy20032017
AT yaoru longtermsurvivalofscreendetectedsynchronousandmetachronousbilateralnonpalpablebreastcanceramongchinesewomenahospitalbasedstudy20032017
AT zhouxingtong longtermsurvivalofscreendetectedsynchronousandmetachronousbilateralnonpalpablebreastcanceramongchinesewomenahospitalbasedstudy20032017
AT xuyali longtermsurvivalofscreendetectedsynchronousandmetachronousbilateralnonpalpablebreastcanceramongchinesewomenahospitalbasedstudy20032017
AT renxinyu longtermsurvivalofscreendetectedsynchronousandmetachronousbilateralnonpalpablebreastcanceramongchinesewomenahospitalbasedstudy20032017
AT xiaomengsu longtermsurvivalofscreendetectedsynchronousandmetachronousbilateralnonpalpablebreastcanceramongchinesewomenahospitalbasedstudy20032017
AT zhuqingli longtermsurvivalofscreendetectedsynchronousandmetachronousbilateralnonpalpablebreastcanceramongchinesewomenahospitalbasedstudy20032017
AT konglingyan longtermsurvivalofscreendetectedsynchronousandmetachronousbilateralnonpalpablebreastcanceramongchinesewomenahospitalbasedstudy20032017
AT maofeng longtermsurvivalofscreendetectedsynchronousandmetachronousbilateralnonpalpablebreastcanceramongchinesewomenahospitalbasedstudy20032017
AT linyan longtermsurvivalofscreendetectedsynchronousandmetachronousbilateralnonpalpablebreastcanceramongchinesewomenahospitalbasedstudy20032017
AT zhangxiaohui longtermsurvivalofscreendetectedsynchronousandmetachronousbilateralnonpalpablebreastcanceramongchinesewomenahospitalbasedstudy20032017
AT shensongjie longtermsurvivalofscreendetectedsynchronousandmetachronousbilateralnonpalpablebreastcanceramongchinesewomenahospitalbasedstudy20032017
AT sunqiang longtermsurvivalofscreendetectedsynchronousandmetachronousbilateralnonpalpablebreastcanceramongchinesewomenahospitalbasedstudy20032017